Skip to main content
SpringerLink
Log in

Progress and challenges in neuroendocrine and neural crest tumours: molecular imaging and therapy

  • Focus on
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Oberndorfer S. Karzinoide tumoren des dünndarms. Frankf Z Pathol. 1907;1:426–32.

    Google Scholar 

  2. Modlin IM, Shapiro MD, Kidd M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum Pathol. 2004;35(12):1440–51.

    Article  PubMed  Google Scholar 

  3. Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, et al. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest. 2009;32(4):360–9.

    CAS  PubMed  Google Scholar 

  4. Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EG, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol. 2009;71(3):199–213.

    Article  PubMed  Google Scholar 

  5. Taïeb D, Sebag F, Barlier A, Tessonnier L, Palazzo FF, Morange I, et al. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med. 2009;50(5):711–7.

    Article  PubMed  Google Scholar 

  6. Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, et al. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50(4):513–9.

    Article  PubMed  Google Scholar 

  7. Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab. 2009;94(4):1295–301.

    Article  CAS  PubMed  Google Scholar 

  8. Neels OC, Koopmans KP, Jager PL, Vercauteren L, van Waarde A, Doorduin J, et al. Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3, 4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res. 2008;68(17):7183–90.

    Article  CAS  PubMed  Google Scholar 

  9. Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68 Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009;30(4):281–6.

    Article  PubMed  Google Scholar 

  10. Modlin IM, Kidd M, Drozdov I, Siddique ZL, Gustafsson BI. Pharmacotherapy of neuroendocrine cancers. Expert Opin Pharmacother. 2008;9(15):2617–26.

    Article  CAS  PubMed  Google Scholar 

  11. de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res. 2009;42(7):873–80.

    Article  PubMed  Google Scholar 

  12. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138–46.

    Article  CAS  PubMed  Google Scholar 

  13. Hendlisz A, Flamen P, Van den Eynde M, Borbath I, Demetter P, Demolin G, et al. Locoregional and radioisotopic targeted treatment of neuroendocrine tumours. Acta Gastroenterol Belg. 2009;72(1):44–8.

    CAS  PubMed  Google Scholar 

  14. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68 Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50(8):1214–21.

    Article  PubMed  Google Scholar 

  15. Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50(6):858–64.

    Article  CAS  PubMed  Google Scholar 

  16. Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52(7):784–90.

    Article  PubMed  Google Scholar 

  17. Goldsmith SJ. Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncol. 2009;5(1):75–84.

    Article  CAS  PubMed  Google Scholar 

  18. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100(18):1282–9.

    Article  PubMed  Google Scholar 

  19. Yu R, Nissen NN, Chopra P, Dhall D, Phillips E, Wei M. Diagnosis and treatment of pheochromocytoma in an academic hospital from 1997 to 2007. Am J Med. 2009;122(1):85–95.

    Article  PubMed  Google Scholar 

  20. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5(7):382–93.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The author is grateful to Ms Catherine Wrenn for her advice and editorial support.

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences and Technologies and Center of Molecular and Cellular Imaging (IMAGO), University of Milan, Milan, Italy

    Giovanni Lucignani

  2. Department of Diagnostic Services, Unit of Nuclear Medicine, San Paolo Hospital, Via Antonio di Rudinì, 8, 20142, Milan, Italy

    Giovanni Lucignani

  3. Nuclear Medicine Division, Department of Diagnostic Imaging and Therapy, Istituto Nazionale Tumori IRCCS Foundation, Milan, Italy

    Emilio Bombardieri

Authors
  1. Giovanni Lucignani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emilio Bombardieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Lucignani.

Additional information

“Focus on…” abridgements aim to highlight papers published within the past year and draw extensively on the texts and summaries of the articles referenced. Less recent citations are also included when deemed useful to provide background information on the topic reviewed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lucignani, G., Bombardieri, E. Progress and challenges in neuroendocrine and neural crest tumours: molecular imaging and therapy. Eur J Nucl Med Mol Imaging 36, 2081–2088 (2009). https://doi.org/10.1007/s00259-009-1286-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-009-1286-7

Keywords

Search

Navigation